[Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration].

The efficacy of naftidrofuryl ( Dusodril ) for treatment of stage II arterial occlusive disease was evaluated in a controlled multi-centre study in a total of 104 out-patients with angiographically documented localization of occlusion. The therapeutic effect was assessed over three months by measurements of walking distance using standardized treadmill conditions. Further parameters were venoocclusive plethysmography and Doppler ultrasonography measurement of pressures.

[The effect of etofibrate on serum cholesterol and triglycerides (author's transl)].

Etofibrate retard administered in a daily dose 500 mg to 14 outpatients with hyperlipoproteinemia type IIa decreased the cholesterol only 1.7% after a treatment period of 6 weeks. After a treatment of 12 weeks the serum cholesterol was higher in 10 of the 14 patients than in the pretreatment period.

[Gastroscopy and coronary risk (author's transl)].

In 50 patients, both outpatients and inpatients, electrocardiograms were recorded in different phases during esophagogastroscopy. The changes which occurred, such as tachycardia, arrhythmias, and disorders of repolarization are discussed. The increased frequency during the initial stage of the endoscopy, which may assume an already dangerous dimension for patients with coronary heart disease, merits particular attention.